Comparative Effectiveness of SGLT2 Inhibitor and GLP-1 Receptor Agonist on Kidney and Cardiovascular Outcomes by Kidney Failure Risk
Compared with GLP-1 RA, SGLT2i had comparable risks of mortality, perhaps a lower risk of kidney failure, but modestly higher risk of cardiovascular events in the entire cohort. However, GLP-1 RA were more beneficial in those with moderate kidney failure risk and SGLT2i more beneficial in those with high kidney failure risk.
Authors
- Catherine G. Derington (ORCID: https://orcid.org/0000-0001-7382-4607)
- Sydney E. Hartsell (ORCID: https://orcid.org/0000-0001-7328-3732)
- Robert E. Boucher (ORCID: https://orcid.org/0000-0002-5455-002X)
- Michael J Throolin
- Jincheng Shen
- Ravinder Singh
- Stavros Drakos
- McKenna R. Nevers
- Christa Curtis
- Guo Wei
- Amara Sarwal
- Srinivasan Beddhu
Institutions
- Spencer Foundation (US)
- VA Salt Lake City Healthcare System (US)
- University of Colorado Anschutz Medical Campus (US)
Publication Details
- Journal
- Journal of the American Society of Nephrology
- Published
- 2026-01-13
- DOI
- https://doi.org/10.1681/asn.0000001016
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00